Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3059 |
ALK-IN-1
AP26113,Brigatinib,AP26113-analog |
EGFR; IGF-1R; ALK | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
ALK-IN-1 (AP26113) 是一种高效的、选择性的 ALK 激酶抑制剂。 | |||
T10286 |
ALK/ROS1-IN-1
|
Others | Others |
ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme). | |||
T72931 | TRK/ALK-IN-1 | ||
TRK/ALK-IN-1 是一种有效的 TRK 和 ALK 双重抑制剂。TRK/ALK-IN-1 在酶促测定中与抗增殖活性非常吻合,对 TRKA、ALKIC50值分别为 2.2、9.3 和 38 nM< sup>WT 和 ALKL1196M。TRK/ALK-IN-1具有研究癌症疾病的潜力。 | |||
T79392 | ALK/EGFR-IN-1 | EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
ALK/EGFR-IN-1(Compound 8l)是一款高效的ALK/EGFR双重抑制剂,专门针对EGFR和ALK的磷酸化过程进行抑制。该化合物对H1975细胞内的EGFRL858R/T790M突变体和BaF3细胞内的EML4-ALK表达类型表现出优异的抑制活性,其IC50值分别为4.3 nM和3.6 nM。ALK/EGFR-IN-1用于非小细胞肺癌(NSCLC)的科学研究具有重要应用价值。 | |||
T3678 |
Entrectinib
RXDX-101,恩曲替尼,NMS-E628 |
Trk receptor; ROS; ALK; Autophagy; ROS Kinase | Angiogenesis; Autophagy; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Entrectinib (RXDX-101) 是一种可口服的 Trk、ROS1和 ALK 抑制剂,具有抗肿瘤和中枢神经活性,抑制 TrkA、TrkB、TrkC、ROS1 和 ALK 的 IC50值分别为 1、3、5、12 和 7 nM。 | |||
T83146 |
ALK-IN-27
|
||
ALK-IN-27(化合物1)是一种有效的ALK抑制剂,展现出抗肿瘤活性。在Ba/F3 CLIP1-LTK细胞中,ALK-IN-27的IC50为2.7 nM。 | |||
T61443 | Trk-IN-7 | ||
Trk-IN-7 (compound I-6) is a highly potent inhibitor of TRK, exhibiting IC50 values ranging from 0.25-10 nM for TRKA, TRKB, and TRKC, respectively. In addition, Trk-IN-7 demonstrates notable inhibition against EML4-ALK (IC50 <15 nM), as well as ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC50 = 5-50 nM) [1]. | |||
T79393 | ALK/EGFR-IN-2 | ||
ALK/EGFR-IN-2 是一种高效的 ALK 和 EGFR 双重抑制剂,能够诱导癌细胞凋亡及 G0/G1 细胞周期停滞。此化合物在 H1975、PC9 和 Baf3-EML4-ALK 癌熙胞株的增殖抑制实验中,其 IC50 值分别为0.0034、0.0065 和 0.0018 μM,表明其对这些癌熙胞系具有显著的抑制作用。 | |||
T74522 | ALK-IN-21 | ||
ALK-IN-21(Compound B10)是一款高效的ALK抑制剂,其针对ALKWT、ALKL1196M和ALKG1202R的IC50值依次为4.59 nM、2.07 nM和5.95 nM。该化合物能显著抑制ALK阳性的Karpas299与H2228细胞系的增殖,均展现出0.07 μM的IC50值。ALK-IN-21主要用于研究间变性大细胞淋巴瘤。 | |||
T79394 | ALK/EGFR-IN-3 | ||
ALK/EGFR-IN-3 为ALK与EGFR的强效双重抑制剂,有效遏制H1975、PC9以及Baf3-EML4-ALK癌细胞系的生长,其IC50值分别为0.1360、0.0332及0.0339 μM。 | |||
T83856 |
AP-1
|
||
AP-1是一种微型化的蛋白质水解靶向嵌合体(PROTAC),由吲哚美辛(±)连接的间变性淋巴瘤激酶(ALK)配体和E3泛素连接酶配体通过超短连接器相连。在10至300 nM浓度范围内使用时,AP-1能高效降解Karpas-299细胞中高表达的ALK融合蛋白NPM-ALK,此效应可被蛋白酶体抑制剂MG-132阻断。它还能降解在SN-N-SH和NCI H3122细胞中表达的ALK融合蛋白EML4-ALK及含有苯丙氨酸至亮氨酸替换突变(ALKF1174L)的ALK。AP-1对依赖ALK的Karpas-299细胞具有细胞毒性(IC50 = 0.1265 nM),但对非ALK依赖的THP-1细胞无细胞毒性(IC50 = 2,704 nM)。在给药剂量为25, 50, 和100 mg/kg时,能减小NCI H3122小鼠移植瘤模型中的肿瘤体积。 | |||
T70060 |
PF-06463922 acetate
|
||
PF-06463922 acetate is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against all known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. PF-06463922 is in clinical trials for the treatment of non–small cell lung cancer (NSCLC). | |||
T38584 |
ALK-IN-12
|
||
ALK-IN-12 is a highly potent and orally active inhibitor of anaplastic lymphoma kinase (ALK), demonstrating an exceptional IC50 value of 0.18 nM. Additionally, ALK-IN-12 displays inhibitory activity against insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (InsR), with IC50 values of 20.3 nM and 90.6 nM, respectively. Notably, its antitumor effects have been observed, making it a promising compound for targeted cancer therapy. | |||
T62613 |
ALK5-IN-26
|
||
ALK5-IN-26 (EX-22) 是一种 ALK(Activin receptor-like kinase) 的抑制剂。ALK5-IN-26 对 ALK5 (IC50≤1 nM) 具有抑制作用。ALK5-IN-26 能够用于研究癌症。 | |||
T37585 | Ensartinib | ||
Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC50: 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC50: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring N... | |||
T79363 | APG-2449 | ROS Kinase | Tyrosine Kinase/Adaptors |
APG-2449为口服活性的ALK/ROS1/FAK抑制剂,在非小细胞肺癌(NSCLC)的小鼠模型中显示出显著的抗肿瘤效果。 | |||
T61872 |
Trk-IN-10
|
||
Trk-IN-10 (Compound 14j) is a highly effective inhibitor of TRK, with an IC50 of 0.86 nM against TrkA and 6.92 nM against TrkA G595R. As an RTK, Trk plays a crucial role as a drug target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) demonstrates superior selectivity in inhibiting Trk, which has potential implications for toxicity reduction [1]. |